- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Cretostimogene Induces Acute Th1-Skewed Inflammation in BCG-Unresponsive CIS-Containing Non-Muscle Invasive Bladder Cancer (BOND-003 Cohort C) The post IBCN 2026 – BOND-003 Cohort C and Urinary Cytokines Poster appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Urinary Tumor DNA is Prognostic for Recurrence in Patients with BCG-Unresponsive Disease Receiving Cretostimogene Grenadenorepvec on BOND-003 Cohort C The post IBCN 2026 – BOND-003 Cohort C and Urinary Tumor DNA Podium appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Cretostimogene Grenadenorepvec: Mechanism, Clinical Development, and Emerging Evidence in Non-Muscle Invasive Bladder Cancer The post Bladder & Kidney Cancer Academy 2026 Podium appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Efficacy and Safety of Intravesical Cretostimogene Grenadenorepvec Plus Gemcitabine in High-Risk BCG-Exposed Or BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (CORE-008 Cohort CX) The post NSAUA 2026 – CORE-008 Cohort CX Topline Poster appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Clinical and Pharmacokinetic/Pharmacodynamic Insights From CORE-008 Cohort A – Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer The post NSAUA 2026 – CORE-008 Cohort A and PK/PD Poster appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Topline Results From BOND-003 Cohort P – A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with HG Ta/T1 (Without CIS) The post NSAUA 2026 – BOND-003 Cohort P Topline Poster appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Outcomes of Cretostimogene Grenadenorepvec in Second-Line High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ: Analysis from BOND-003 Cohort C The post NSAUA 2026 – BOND-003 Cohort C Second Line Poster appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Cretostimogene Induces Acute Th1 Skewed Inflammation in BCG-Unresponsive CIS-Containing Non-Muscle Invasive Bladder Cancer (BOND-003 Cohort C) The post NSAUA 2026 – BOND-003 Cohort C and Cytokines Poster appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Exploring Cretostimogene's Combination Potential in NMIBC Beyond Monotherapy The post Albert Institute 2026 – Cretostimogene’s Combination Potential appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.
Clinical and Pharmacokinetic/Pharmacodynamic Insights from CORE-008 Cohort A: Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer The post SCSAUA 2026 – CORE-008 Cohort A and PK/PD Insights Poster appeared first on Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology.